literature

HIV mutation literature information.

Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries.

PMID: 35061671 2022 PloS one

Result: Mutations with a frequency higher than 1% in the study cohort, in clusters and outside clusters were E138A (5.3% vs 5.7%, overall, 5.6%, p = 0.830), K103N (3.5% vs 2.7%, overall 2.9%, p = 0.515), and

Discussion: The predominant NNRTI DRMs included E138A/G, which is the natural polymorphic mutation for sub-subtype A6, was previously shown to have a prevalence of 7% frequency in Russian HIV-infected patients, and is associated with low-level DR to rilpivirine, which is not taken into account in the assessment of PDR; V106I, which alone causes a minimal reduction in NNRTI susceptibility; and K103N/S, which causes a large reduction in NVP and EFV susceptibility.

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Table: V106I/V

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

PMID: 35001501 2022 Journal of the International AIDS Society

Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, G190A/S/E,H221Y, P225H, F227L/C/R,

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.

PMID: 35300056 2022 Pharmacogenomics and personalized medicine

Result: The most common non-nucleoside reverse transcriptase inhibitors (NNRTIs) associated mutation was V179D (4.97%, 43/865), followed by V179E (4.05%, 35/865) and V106I (2.89%, 25/865).

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

PMID: 35336931 2022 Viruses

Abstract: DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up.

Result: Baseline resistance mutations (K103N, V106I + E138A, and V108I, respectively) were detected in three patients (3.4%).

Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients.

PMID: 35140966 2022 Clinical case reports

Discussion: In a study of patients entering the SENSE trial for first-line ART in Europe, Russia, and Israel, 13.9% of patients presented with at least one polymorphic mutation in their baseline plasma (V90I, V106I, or E138A), without any impact on the virological outcomes of an etravirine-based ART program.

High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.

PMID: 34212033 2021 BioMed research international

Result: The most frequently detected DRMs were M184I/V (68/82; 82.9%), K70E/R (16/82; 19.5%), and T215F/Y (17/82; 20.7%) to NRTI and K103N/S (51/82; 62.1%), P225H (15/82; 18.2%), and V106A/I/M (11/82; 13.4%) to NNRTI (Figure 1).

Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive Paediatric HIV-1 Outbreak in Larkana, Pakistan.

PMID: 34484134 2021 Frontiers in microbiology

Table: V106I

HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.

PMID: 34377002 2021 Infection and drug resistance

Result: The major NNRTI DRMs were V179D/E (37.9%, 149/393), V106I/M (25.7%, 101/393), and K103N/Q (25.2%, 99/393) (Table 3).

Table: V106I/M

Discussion: V106I/M, K103N/Q, G190A/S, and Y181C were the major NNRTI-associated mutations, similar to those in other cities in China and other countries, and showed broad-spectrum resistance possibly caused by the wide use of NNRTIs.

HIV-1 molecular transmission network among sexually transmitted populations in Liaoning Province, China.

PMID: 34260561 2021 Medicine

Result: Among them, 9 cases were protease inhibitor-related resistance, and the main resistance sites were L33F, V82A, Q58E, M46L, M46I; There were 4 cases of nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V75VI, K219Q, T215A, K65R; There were 5 cases of non-nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V179E, A98G, V106I, Y181C, G190S

Browser Board

Co-occurred Entities

Filtrator